Other
Cytoreductive Surgery
0
Pipeline Programs↗
2
Active Trials↗
1
Companies Involved↗
Cytoreductive Surgery is an early-stage landscape with 0 programs across 1 company. The most active players are Japan Clinical Oncology Group.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
11
clinical trials
Completed6 · 55%
Terminated2 · 18%
Not yet recruiting1 · 9%
Recruiting1 · 9%
Withdrawn1 · 9%
Clinical Trials
Trial Activity
11 trials
Efficacy and Safety of Trifluridine/tipiracil (TAS-102) Combined with Bevacizumab and Putalimab in the Treatment of Patients with MCRC After Cytoreductive Surgery: a Single-arm, Single-center Clinical Study
Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT06882915·20 enrolled
Single Dose Tranexamic Acid in Reducing Blood Loss During Cytoreductive Surgery and HIPEC
Completed·—·N/A·NCT03646474·46 enrolled
Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for MPM
Terminated·—·Phase 1·NCT02838745·7 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)